Dayabitis dɔn bi wan sik we bɔku pipul dɛn kin gɛt na wi kɔntri. Sɔntɛm wan pan yu famili, yu padi, ɔ ivin yusɛf kin gɛt dis sik. Tayp 2 Dayabitis mɔ na siriɔs wɛlbɔdi prɔblɛm we de afɛkt pas 400 milyɔn pipul dɛn ɔlsay na di wɔl. If dɛn nɔ kɔntrol am fayn, i kin mek yu gɛt prɔblɛm dɛn we de mek yu gɛt prɔblɛm lɛk di kidni we de pwɛl, we yu nɔ de si fayn, at sik, ɛn paralayz. Pan ɔl we pas 30 kayn mɛrɛsin de fɔ kɔntrol dis sik, nɔr pan dɛn nɔ go ebul fɔ "krɔs" am kɔmplit wan. Bɔt... nyu risach dɔn sho se dis tin kin chenj. Lɛ wi si aw.
Wetin wi dɔn de tink bɔt dayabitis fɔ lɔng tɛm
Na lɛk twɛnti ia so dɔn pas, if yu aks wan masta sabi pɔsin bɔt dayabitis, i go se di men tin we kin mek dis apin na ‘insulin resistance’. Fɔ tɔk am simpul wan, insulin na ɔmon we wi pankrias de mek. di men wok we i de du na fכ tek di glukכs (shuga) we de kכmכt frכm di it we wi de it εn put am insay di sεl dεm na wi bכdi. Na da tɛm de di sɛl dɛn kin gɛt ɛnaji.
Tink bɔt insulin as ki, ɛn sɛl dɛn lɛk domɔt. Insulin na di ki we de opin di domɔt so dat glukɔs go ebul fɔ go insay di sɛl dɛn.
Bɔt, di sɛl dɛn na pɔsin we gɛt insulin rɛsistɛns nɔ de ansa dis insulin fayn fayn wan. I tan lɛk se di kihol we de na di domɔt dɔn rɔsti. Dɔn, bikɔs dɛn nɔ ebul fɔ opin di domɔt, di pankrias gɛt fɔ mek mɔ insulin ki dɛn. As tɛm de go, di pankrias kin wik bikɔs i de wok tranga wan. Na da tɛm de tayp 2 dayabitis kin apin. Dis na di stori we wi dɔn no fɔ lɔng tɛm.
Di nyu tin we dɛn dɔn fɛn we impɔtant pas ɔl: Di stori bɔt beta sɛl dɛn
Naw sayɛnsman dɛn dɔn kam fɔ no se di prɔblɛm nɔto jɔs we pɔsin nɔ ebul fɔ yuz insulin. Di ɔda af pan di prɔblɛm de na wi beta sɛl dɛn . Dis na di sɛl dɛn we de sidɔm insay di pankrias ɛn dɛn tan lɛk smɔl smɔl faktri dɛn we de mek insulin.
כl di beta sεl dεm we wi bכdi nid de kכmכt insay di fכs fכs ia dεm na wi layf. Bɔt dɛn kin bɔn sɔm pipul dɛn wit mɔ beta sɛl pas ɔda wan dɛn. So, ivin if dɛn gɛt insulin rɛsistɛns leta na dɛn layf, dɛn beta sɛl faktri dɛn kin mek mɔ insulin fɔ kɔmpɛns.
Bɔt we pɔsin we dɛn bɔn wit we nɔ gɛt bɛtɛ beta sɛl dɛn gɛt insulin rɛsistɛns, di sɛl dɛn we lɛf fɔ wok tranga wan pas aw dɛn ebul fɔ wok. Afta sɔm tɛm, dɛn sɛl dɛn de kin taya ɛn day. Na dɛn pipul ya kin gɛt tayp 2 dayabitis.
So, di big gol naw na fɔ fɛn wan drɔg we go ebul fɔ mek dɛn beta sɛl ya we de day bak ɔ mek di nɔmba fɔ di sɛl dɛn we de de bɔku. If dɛn ebul fɔ du dat, dɛn go ebul fɔ mɛn tayp 2 dayabitis, nɔto jɔs fɔ kɔntrol am.
Di las drɔgs we dɔn briŋ op
As sayɛnsman dɛn bin de du risach bɔt dis, dɛn bin fɛn wan mɛrɛsin we go ɛp fɔ mek dɛn beta sɛl dɛn ya gro. Dɛn kɔl am harmine . Na kɔmpawnd we dɛn kin si na difrɛn plant dɛn ɔlsay na di wɔl.
dis dכg we dεn kכl harmine de wok bay we i de blכk wan εnzym we dεn kכl DYRK1A insay di beta sεl dεm. we dεn blכk dis, di beta sεl dεm kin bigin fכ sheb, bכku, εn in saiz bכku. Insay di tɛst dɛn we dɛn bin du pan mays, di mays dɛn we gɛt dayabitis we dɛn gi dis mɛrɛsin bin gɛt tri tɛm inkris pan di beta sɛl saiz! Na da sem tɛm de, di shuga we dɛn bin gɛt na dɛn blɔd bin kam bak lɛk aw i bin de.
Bɔt, fɔ mek dis go bifo pan mɔtalman, sayɛnsman dɛn bin kam fɔ no se dɛn nid ɔda tin. So, dɛn bin tɛst di harmine drɔg wit ɔda klas drɔgs we dɛn dɔn ɔlrɛdi yuz fɔ dayabitis. Dɛn kɔl da klas de fɔ drɔgs GLP1R agonist . If yu na pɔsin we de tek dayabitis mɛrɛsin, yu go dɔn yɛri bɔt dɛn nem ya: `(exenatide)`, `(liraglutide)`, `(lixisenatide)` na sɔm pan di mɛrɛsin dɛm we de na dis klas. Dɛn de wok bay we dɛn de mek di beta sɛl dɛn wok ɛn ɛnkɔrej dɛn fɔ mek insulin.
So, wetin bin apin we dɛn put dɛn tu drɔgs ya togɛda? Di tin dɛn we bin apin bin rili wɔndaful!
| Tritmɛnt we dɛn bin de yuz | Beta sel we de gro (insay 24 awa) . |
|---|---|
| Harmine nɔmɔ | Wan growth we na lɛk 2% . |
| Harmine + GLP1R agonist drɔg | I go rich 8% growth! |
| insay sכm kes dεm, dεn si se di beta sεl nכmba dεm de inkrεs bay 40% insay sכm sכm 4 dez. | |
Dɛn rizɔlt ya dɔn mek pipul dɛn gɛt bɔku kɔnfidɛns se dis tritmɛnt we dɛn go yuz go wok fayn pan mɔtalman bak.
Di chalenj we de bifo ɛn wetin mek dis impɔtant?
Di big chalenj naw na aw fɔ deliv dis drɔg miks dairekt to di beta sɛl dɛn. Sayɛnsman dɛn de se, "Wi gɛt wan paket fɔ mɛn di beta sɛl dɛn, bɔt wi nɔ no di rayt adrɛs fɔ sɛn am to." As sɔlv, dɛn de tink fɔ yuz sɔntin we dɛn kɔl monoklonal antibodies . Dɛn tin ya tan lɛk smat kɔriɔ savis we kin kɛr wi drɔg paket go dairekt to di beta sɛl dɛn.
Wetin mek dis rili impɔtant?
Jɔs tink bɔt dat, di mɛrɛsin dɛn we dɛn de yuz naw fɔ gɛt dayabitis, jɔs de kɔntrol di shuga we de na di blɔd. If yu stɔp fɔ tek di mɛrɛsin, di sik go kam bak.
Di wangren tin we dɔn kam nia fɔ sɔlv am fɔ ɔltɛm te naw na bariatric ɔpreshɔn . Dat min se dɛn fɔ du ɔpreshɔn fɔ mek yu nɔ gɛt bɔku bɔku bɔdi. Bɔku tɛm dis kin put dayabitis pan rɛmishɔn. Bɔt fɔ di 400 milyɔn pipul dɛn na di wɔl, ɔpreshɔn nɔ fayn. I dia, i kin gɛt prɔblɛm, ɛn i kin tek lɔng tɛm fɔ mek i wɛl.
Bɔt if dis nyu drɔgs kɔmbayn wok fayn, i kin chenj bɔku bɔku pipul dɛn layf ɔlsay na di wɔl. I nɔ jɔs de stɔp di simptom dɛm, i de mek di rut kɔz fɔ di sik kam bak, we na di beta sɛl dɛm we de lɔs.
Mɛsej we dɛn kin kɛr go na os
- Tayp 2 dayabitis nɔto jɔs bikɔs i nɔ gɛt insulin. di dכn pan di nכmba fכ di beta sεl dεm we de prodyuz insulin na di mכtalman bak.
- Naw sayɛnsman dɛn de tray fɔ fɛn wan mɛrɛsin we go mek dɛn beta sɛl dɛn ya we dɔn lɔs gro bak.
- rεsכch dεn sho se we dεn kכmbayn harmine wit wan GLP1R agonist dכg we dεn dכn yuz, i de mek di beta sεl dεm gro fast fast.
- Pan ɔl we dis stil de na di risach stej, i gɛt bɔku op fɔ wan tritmɛnt we go ebul fɔ mɛn dayabitis kpatakpata tumara bambay.
- Pan ɔl we ɔl dis na op fɔ tumara bambay, i impɔtant fɔ kɔntrol yu dayabitis fɔ naw. Fɔ fala di advays we yu dɔktɔ gi yu.
💬 Comments (0)
No kɔmɛnt nɔ de yet. Ad yu kɔmɛnt ya fɔ di fɔs tɛm.
Ad yu kɔmɛnt